2 April 2020 - Deborah Wilkes
Dermapharm has reported its financial results for 2019, Novartis and Aurobindo have terminated a transaction, and Stada has made a people appointment in Portugal.
Dermapharm reports 2019 results
German pharmaceutical company Dermapharm reported sales up by 23% to EUR701 million (USD758 million) in 2019 following a series of acquisitions.
Chief executive officer Hans-Georg Feldmeier said Dermapharm had “consistently implemented its three-pillar strategy of in-house product development, further internationalisation and successful acquisitions”.
At the start of 2019, Dermapharm announced that it was acquiring Euromed Botanicals, the Spanish supplier of standardised herbal extracts and natural active ingredients (click here to read the News story).
In March 2019, the company took a 20% stake in a group of companies specialising in the production of medical cannabis for pharmaceutical applications. The deal covered four FYTA businesses in the Netherlands and Germany.
In July 2019, Dermapharm acquired a 70% stake in German healthy nutrition company Fitvia (click here to read the News story).
Furthermore, Dermapharm has just completed the acquisition of the Allergopharma allergy business from Germany’s Merck KGaA.
Dermapharm's Earnings Before Interest, Taxes, Depreciation and Amortisation (EBITDA) were up by 21% year-on-year to EUR169 million in 2019, giving an EBITDA margin of 24.0%.
EBITDA adjusted for one-off costs of EUR9.1 million was up by around 24% to EUR178 million. The adjusted EBITDA margin was 25.3%.
Dermapharm is a family-owned company through Themis Beteiligungs-Aktiengesellschaft, which remains the majority shareholder after an Initial Public Offering (IPO) in early 2018.
The Dermapharm group includes the Anton Hübner OTC business in Germany, which markets the Tannenblut range of herbal remedies. Dermapharm also owns the ACIS and Mibe generics subsidiaries, and the Tiroler Nussöl suncare business.
Novartis and Aurobindo end deal
Novartis and Aurobindo have terminated the planned sale of Novartis’ Sandoz US generic oral solids and dermatology businesses to Aurobindo Pharma USA.
The decision had been taken as “approval from the US Federal Trade Commission (FTC) for the transaction was not obtained within anticipated timelines”, said Novartis.
Sandoz will continue to operate its oral solids and dermatology business as part of the Sandoz US business.
Stada hires in Portugal
Germany’s Stada has hired Sandoz’ Tiago Baleizão as general manager of its Ciclum Farma subsidary in Portugal.
Baleizão was previously retail business unit lead for Sandoz in Portugal. Before joining Sandoz in 2017, he spent nine years with Pfizer in roles covering Asia, Europe, Latin America and the Middle East.